Astra Space, Inc. - Class A Common Stock ASTR 深 滬
等待開盤 11-04 09:30:00 美东时间
0.539
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.539
- 總市值 1223.88万
- 52周最高 6.363
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.4922
- 委 比 0.00%
- 總股本 2270.65万
- 歷史最高 337.05
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.4922
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Astra Exploration Begins Phase II Drilling at La Manchuria Project
An announcement from Astra Exploration Inc ( ($TSE:ASTR) ) is now available. As...
10-30 00:07
首个且唯一在美开展桥接试验的抗PD-1单抗 复宏汉霖汉斯状美国桥接试验完成全部受...
内容来源：复宏汉霖 H药在美国的ES-SCLC桥接试验已完成全部患者入组，为后续向FDA递交BLA奠定坚实基础 该研究由复宏汉霖美国临床、注册团队自主管理...
10-22 17:36
百洋医药ZAP-X火星舟亮相国际放疗盛会ASTRO，展示脑组织保护新成果
近日，全球规模最大、影响力最广的放射肿瘤学学术盛会——第67届美国放射肿瘤学会（ASTRO）年会在美国旧金山隆重召开，汇聚了超1万名来自世界各地的顶尖放疗专家...
10-16 13:50
Crypto whales heavily shorting Bitcoin, major altcoins - report
Crypto whales are ramping up short positions on bitcoins and major altcoins, with the entity known as the “Trump Insider Whale” intensifying its bearish stance on Bitcoin (BTC-USD), according to Arkha...
10-15 00:51
复宏汉霖全球首发胃癌围术期以免疫单药取代术后辅助化疗的治疗方案
据“浦东发布”官微，10月9日，复宏汉霖（02696.HK）宣布公司自研创新型PD-1抑制剂H药汉斯状®（斯鲁利单抗，欧洲商品名Hetronifly®）联合化疗...
10-10 11:05
Johnson & Johnson's TREMFYA Shows 48-Week Remission Results In Ulcerative Colitis With First Fully Subcutaneous IL-23 Inhibitor
Patients treated with subcutaneous TREMFYA® achieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO studyClinical and endoscopic
10-07 20:10
Astra Exploration Secures C$5.0M for Latin American Projects
Astra Exploration Inc ( ($TSE:ASTR) ) has provided an update. Astra Exploration...
09-30 06:07
Reported Sunday, Veracyte Announces BALANCE Trial Results Showing PAM50 Biomarker Predicts Apalutamide Benefit With Salvage Radiation In Prostate Cancer
Findings from the first prospective validation trial for biomarker presented at ASTRO 2025
09-29 14:34
RaySearch Brings Next-Level Innovation to ASTRO 2025
STOCKHOLM, Sept. 26, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce its participation at ASTRO in San Francisco, California, September 28-30, where state of the a...
09-26 15:38
Johnson & Johnson Receives FDA Approval For Subcutaneous Induction Regimen Of TREMFYA; TREMFYA Offers The Flexibility Of Self-Administration From The Start Of Treatment, Building On The Prior Approval Of Subcutaneous Induction In Crohn's Disease;
HORSHAM, Pa., Sept. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of TREMFYA®
09-20 05:32
